CNS Disorders  >>  crenezumab (RG7412)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
crenezumab (RG7412) / AC Immune
ABBY, NCT01343966 / 2010-021926-37: A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease

Completed
2
448
US, Canada, Europe
MABT5102A, placebo
Genentech, Inc.
Alzheimer's Disease
02/14
02/14
BLAZE, NCT01397578 / 2010-022598-32: A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Completed
2
91
US, Europe
MABT5102A, placebo
Genentech, Inc.
Alzheimer's Disease
04/14
04/14
NCT01723826 / 2012-003242-33: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

Completed
2
360
Europe, Canada, US
Crenezumab, RO5490245
Genentech, Inc.
Alzheimer's Disease
02/17
02/17
API ADAD Colombia , NCT01998841: A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

Completed
2
252
RoW
Crenezumab, MABT5102A, Placebo
Genentech, Inc., Banner Alzheimer's Institute, National Institute on Aging (NIA)
Alzheimer's Disease
03/22
08/23
NCT03977584: Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

Completed
2
114
RoW
Crenezumab, MABT5102A, Placebo, [^18F]GTP1
Hoffmann-La Roche, Banner Alzheimer's Institute, National Institute on Aging (NIA)
Alzheimer Disease
04/22
04/22

Download Options